Navigation Links
Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015
Date:1/28/2016

LONDON, Jan. 28, 2016 /PRNewswire/ -- Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, "Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015" provides an overview of Heterozygous familial hypercholesterolemia (heFH) clinical trials scenario. This report provides top line data relating to the clinical trials on Heterozygous familial hypercholesterolemia (heFH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Download the full report: https://www.reportbuyer.com/product/3576987/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
2. Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
3. ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease
6. PCSK9 and Other Novel Hypercholesterolemia Drugs
7. Global Hypercholesterolemia Market 2014-2018
8. Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
9. Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
10. Global Liquid Biopsy Markets Market Report 2016-2020 - Blood Tests Replace Surgical Biopsies / Single Screening Test for all Cancers Announced
11. Disposable Syringes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... , May 3, 2017  West Pharmaceutical Services, ... solutions for injectable drug administration, announced today that ... and Technical Services, and Diane Paskiet , ... offering presentations focused on West,s expertise in the ... as well as providing commentary on updated industry ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... 22, 2017 , ... Faithfully following pop culture, people today are forever in ... shaped through fitness programs. It carries on to skin nourished, pampered and nurtured to ... radiant smile. CDA has found that just like a perfectly cut and ...
(Date:5/22/2017)... ... 2017 , ... OSF Ventures, the corporate investment arm of ... stage company in San Francisco that has developed software to individualize treatment based ... acted as the lead investor in the round. , Medicine is typically ...
(Date:5/21/2017)... ... May 19, 2017 , ... HealthSmart, the ... of James (Jim) Vertino as Chief Information Officer (CIO). He will be joining ... drives innovation and business performance. He defines strategic roadmaps by reimagining business processes—bridging ...
(Date:5/21/2017)... Viejo, CA (PRWEB) , ... May 20, 2017 ... ... self-animating, paragraph styled corporate text designs created specifically for use in Final Cut ... editing process for all media productions. Pixel Film Studios’ ProParagraph Corporate will deliver ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... brought together a cross-disciplinary group of scholars, policymakers, and activists wanting to address ... and Equity is the third book from a recent series of from ...
Breaking Medicine News(10 mins):